A lawsuit fromSanofi that kept the labeling of its OTC switch Nasacort Allergy 24HR under wraps between approval and launch could be a model for delaying private-label competition.
Sanofi announced on Feb. 4 that Nasacort Allergy 24HR (triamcinolone nasal spray), approved as an OTC in October 2013 and marketed through its U.S
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?